Development of cancer immunotherapy using gene-engineered T cells in a self-antigen mouse model [ 2009 - 2012 ]

Research Grant

Researchers: A/Pr Phillip Darcy (Principal investigator)

Brief description Killer T lymphocytes can penetrate tumours and their transfer into cancer patients has demonstrated some encouraging results, but this form of therapy and other approaches including vaccination remain ineffective in most cancer patients. In this project, we propose to improve the tumour trafficking and anti-tumour activities of killer cells by genetically engineering them with proteins that will enable them to recognise and destroy cancer cells.

Funding Amount $AUD 428,602.70

Funding Scheme Career Development Fellowships

Notes RD Wright Biomedical CDF